Milk epidermal growth factor and gut protection

Area of Science:

• Gastroenterology
• Neonatal Research
• Molecular Biology

Background:

• Maternal milk contains growth factors like epidermal growth factor (EGF) and heparin-binding EGF-like growth factor (HB-EGF), crucial for infant gut development.
• These growth factors act via the EGF-receptor (EGF-R) and play roles in normal intestinal epithelial cell proliferation, differentiation, and maturation.
• Breast milk is a primary source of EGF for the neonatal intestinal mucosa, with HB-EGF present in lower concentrations.

Purpose of the Study:

• To investigate the role of EGF and HB-EGF in intestinal health and disease, particularly in the context of necrotizing enterocolitis (NEC).
• To evaluate the therapeutic potential of EGF and HB-EGF in preventing or mitigating NEC, a serious condition in premature infants.

Main Methods:

• Utilized an experimental model of NEC in premature infants.
• Administered physiological doses of EGF orally.
• Administered pharmacological doses of HB-EGF orally.

Main Results:

• Oral administration of physiological doses of EGF significantly reduced the incidence and severity of NEC in the experimental model.
• HB-EGF demonstrated protective effects against NEC, but only when administered at pharmacological doses.
• EGF contributes to epithelial protection and mucosal repair in pathophysiological conditions.

Conclusions:

• EGF plays a vital role in intestinal epithelial development and repair, and shows promise as a therapeutic agent for NEC.
• While HB-EGF also offers protection, higher doses are required compared to EGF.
• Further research is needed to establish EGF as an effective therapeutic strategy for intestinal injury in neonates.